The tumor microenvironment (TME) is a complex mass of malignant and nonmalignant cells, signaling molecules, extracellular matrix, and blood vessels. Immunomodulation of the T-cell response within the TME, via inhibition of immune checkpoints and co-inhibitory molecules such as CTLA-4 and PD-1, is a promising cancer therapy. Multiplex immunohistochemistry (mIHC) enables the tracking of multiple markers within the TME, predicting therapeutic response and highlighting new therapeutic targets.
Download this poster from Bethyl Laboratories to discover:
- How to unveil cellular phenotypes in the TME
- The differences between one-color IHC, multiplex IHC, and tyramide signal amplification mIHC
- The advantages of mIHC for investigating the TME